SCHEDULE: Northpond Ventures, Michael Rubin Disclose CAMP4 Holdings

Northpond Ventures entities and Michael P. Rubin have filed an amended Schedule 13G, disclosing their beneficial ownership in CAMP4 THERAPEUTICS CORPORATION as of September 30, 2025.

Summary

• Northpond Ventures II, LP beneficially owns 1,003,193 shares of CAMP4 THERAPEUTICS CORPORATION common stock, representing 2.1% of the class.
• Northpond Ventures III, LP beneficially owns 763,636 shares, representing 1.6% of the class.
• Northpond Ventures, LP (Fund I) beneficially owns 471,415 shares, representing 1.0% of the class.
• Michael P. Rubin, as the managing member of the general partners for all three Northpond funds, beneficially owns an aggregate of 2,238,244 shares, representing 4.8% of the class.
• The beneficial ownership percentages are based on 46,880,185 shares of common stock outstanding as of September 30, 2025.
• The reporting persons expressly disclaim status as a 'group' for purposes of this Schedule 13G.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing disclosing beneficial ownership, not containing performance or forward-looking statements that would indicate positive or negative sentiment.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by institutional investors and their principals, common in the biotechnology or pharmaceutical sector where venture capital funds often hold significant stakes in emerging companies like CAMP4 THERAPEUTICS CORPORATION.

Comparison to Industry Standards

• NA

Related Party Transactions

• Michael P. Rubin is the managing member of Northpond Ventures II GP, LLC, Northpond Ventures III GP, LLC, and Northpond Ventures GP, LLC, which are the general partners of Northpond Ventures II, LP, Northpond Ventures III, LP, and Northpond Ventures, LP, respectively. This structure grants him shared voting and dispositive power over the shares held by these funds.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional and individual ownership stakes in the company, which can influence perceptions of investor confidence and potential future corporate actions.

Next Steps

• NA

Key Dates

Keywords

CAMP4 THERAPEUTICS CORPORATION, Northpond Ventures, Michael P. Rubin, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor